• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jmedgeneJournal of Medical GeneticsVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Med Genet. Dec 2000; 37(12): 897–904.
PMCID: PMC1734496

Neurofibromatosis type 2


Neurofibromatosis type 2 is an often devastating autosomal dominant disorder which, until relatively recently, was confused with its more common namesake neurofibromatosis type 1. Subjects who inherit a mutated allele of the NF2 gene inevitably develop schwannomas, affecting particularly the superior vestibular branch of the 8th cranial nerve, usually bilaterally. Meningiomas and other benign central nervous system tumours such as ependymomas are other common features. Much of the morbidity from these tumours results from their treatment. It is now possible to identify the NF2 mutation in most families, although about 20% of apparently sporadic cases are actually mosaic for their mutation. As a classical tumour suppressor, inactivation of the NF2 gene product, merlin/schwannomin, leads to the development of both NF2 associated and sporadic tumours. Merlin/schwannomin associates with proteins at the cell cytoskeleton near the plasma membrane and it inhibits cell proliferation, adhesion, and migration.

Keywords: NF2; vestibular schwannomma; meningioma; mosaic

Full Text

The Full Text of this article is available as a PDF (160K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Faryniarz AG, Chao MV, Huson S, Korf BR, Parry DM, Pericak-Vance MA, et al. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell. 1987 Jun 5;49(5):589–594. [PubMed]
  • Rouleau GA, Wertelecki W, Haines JL, Hobbs WJ, Trofatter JA, Seizinger BR, Martuza RL, Superneau DW, Conneally PM, Gusella JF. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature. 1987 Sep 17;329(6136):246–248. [PubMed]
  • Narod SA, Parry DM, Parboosingh J, Lenoir GM, Ruttledge M, Fischer G, Eldridge R, Martuza RL, Frontali M, Haines J, et al. Neurofibromatosis type 2 appears to be a genetically homogeneous disease. Am J Hum Genet. 1992 Sep;51(3):486–496. [PMC free article] [PubMed]
  • Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993 Mar 12;72(5):791–800. [PubMed]
  • Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993 Jun 10;363(6429):515–521. [PubMed]
  • Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Strachan T, Ramsden R, Harris R. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992 Dec;29(12):841–846. [PMC free article] [PubMed]
  • Antinheimo J, Sankila R, Carpén O, Pukkala E, Sainio M, Jäskeläinen J. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. 2000 Jan 11;54(1):71–76. [PubMed]
  • Kanter WR, Eldridge R, Fabricant R, Allen JC, Koerber T. Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology. 1980 Aug;30(8):851–859. [PubMed]
  • Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. Q J Med. 1992 Aug;84(304):603–618. [PubMed]
  • Evans DG, Newton V, Neary W, Baser ME, Wallace A, Macleod R, Jenkins JP, Gillespie J, Ramsden RT. Use of MRI and audiological tests in presymptomatic diagnosis of type 2 neurofibromatosis (NF2). J Med Genet. 2000 Dec;37(12):944–947. [PMC free article] [PubMed]
  • Evans DG, Wallace AJ, Wu CL, Trueman L, Ramsden RT, Strachan T. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet. 1998 Sep;63(3):727–736. [PMC free article] [PubMed]
  • Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994 Oct 1;52(4):450–461. [PubMed]
  • Mautner VF, Lindenau M, Baser ME, Hazim W, Tatagiba M, Haase W, Samii M, Wais R, Pulst SM. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996 May;38(5):880–886. [PubMed]
  • Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Strachan T, Harris R. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet. 1992 Dec;29(12):847–852. [PMC free article] [PubMed]
  • Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child. 1999 Dec;81(6):496–499. [PMC free article] [PubMed]
  • Mautner VF, Tatagiba M, Guthoff R, Samii M, Pulst SM. Neurofibromatosis 2 in the pediatric age group. Neurosurgery. 1993 Jul;33(1):92–96. [PubMed]
  • Mautner VF, Lindenau M, Baser ME, Kluwe L, Gottschalk J. Skin abnormalities in neurofibromatosis 2. Arch Dermatol. 1997 Dec;133(12):1539–1543. [PubMed]
  • Thomas PK, King RH, Chiang TR, Scaravilli F, Sharma AK, Downie AW. Neurofibromatous neuropathy. Muscle Nerve. 1990 Feb;13(2):93–101. [PubMed]
  • Kaiser-Kupfer MI, Freidlin V, Datiles MB, Edwards PA, Sherman JL, Parry D, McCain LM, Eldridge R. The association of posterior capsular lens opacities with bilateral acoustic neuromas in patients with neurofibromatosis type 2. Arch Ophthalmol. 1989 Apr;107(4):541–544. [PubMed]
  • Ragge NK, Baser ME, Klein J, Nechiporuk A, Sainz J, Pulst SM, Riccardi VM. Ocular abnormalities in neurofibromatosis 2. Am J Ophthalmol. 1995 Nov;120(5):634–641. [PubMed]
  • Bouzas EA, Parry DM, Eldridge R, Kaiser-Kupfer MI. Visual impairment in patients with neurofibromatosis 2. Neurology. 1993 Mar;43(3 Pt 1):622–623. [PubMed]
  • Martuza RL, Ojemann RG. Bilateral acoustic neuromas: clinical aspects, pathogenesis, and treatment. Neurosurgery. 1982 Jan;10(1):1–12. [PubMed]
  • Sobel RA. Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases. J Neuropathol Exp Neurol. 1993 Mar;52(2):106–113. [PubMed]
  • Evans DG, Ramsden R, Huson SM, Harris R, Lye R, King TT. Type 2 neurofibromatosis: the need for supraregional care? J Laryngol Otol. 1993 May;107(5):401–406. [PubMed]
  • Slattery WH, 3rd, Brackmann DE, Hitselberger W. Hearing preservation in neurofibromatosis type 2. Am J Otol. 1998 Sep;19(5):638–643. [PubMed]
  • Mautner VF, Tatagiba M, Lindenau M, Fünsterer C, Pulst SM, Baser ME, Kluwe L, Zanella FE. Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am J Roentgenol. 1995 Oct;165(4):951–955. [PubMed]
  • Fucci MJ, Buchman CA, Brackmann DE, Berliner KI. Acoustic tumor growth: implications for treatment choices. Am J Otol. 1999 Jul;20(4):495–499. [PubMed]
  • Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997 Jul 2;278(1):51–57. [PubMed]
  • Baser ME, Evans DG, Jackler RK, Sujansky E, Rubenstein A. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer. 2000 Feb;82(4):998–998. [PMC free article] [PubMed]
  • McGaughran JM, Harris DI, Donnai D, Teare D, MacLeod R, Westerbeek R, Kingston H, Super M, Harris R, Evans DG. A clinical study of type 1 neurofibromatosis in north west England. J Med Genet. 1999 Mar;36(3):197–203. [PMC free article] [PubMed]
  • Halliday AL, Sobel RA, Martuza RL. Benign spinal nerve sheath tumors: their occurrence sporadically and in neurofibromatosis types 1 and 2. J Neurosurg. 1991 Feb;74(2):248–253. [PubMed]
  • Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988 Dec;111(Pt 6):1355–1381. [PubMed]
  • Antinheimo J, Haapasalo H, Haltia M, Tatagiba M, Thomas S, Brandis A, Sainio M, Carpen O, Samii M, Jäskeläinen J. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J Neurosurg. 1997 Oct;87(4):610–614. [PubMed]
  • Evans DG, Lye R, Neary W, Black G, Strachan T, Wallace A, Ramsden RT. Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma. J Neurol Neurosurg Psychiatry. 1999 Jun;66(6):764–767. [PMC free article] [PubMed]
  • Zang KD. Cytological and cytogenetical studies on human meningioma. Cancer Genet Cytogenet. 1982 Jul;6(3):249–274. [PubMed]
  • Wolff RK, Frazer KA, Jackler RK, Lanser MJ, Pitts LH, Cox DR. Analysis of chromosome 22 deletions in neurofibromatosis type 2-related tumors. Am J Hum Genet. 1992 Sep;51(3):478–485. [PMC free article] [PubMed]
  • Irving RM, Moffat DA, Hardy DG, Barton DE, Xuereb JH, Holland FJ, Maher ER. A molecular, clinical, and immunohistochemical study of vestibular schwannoma. Otolaryngol Head Neck Surg. 1997 Apr;116(4):426–430. [PubMed]
  • Seizinger BR, Martuza RL, Gusella JF. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature. 1986 Aug 14;322(6080):644–647. [PubMed]
  • Watson CJ, Gaunt L, Evans G, Patel K, Harris R, Strachan T. A disease-associated germline deletion maps the type 2 neurofibromatosis (NF2) gene between the Ewing sarcoma region and the leukaemia inhibitory factor locus. Hum Mol Genet. 1993 Jun;2(6):701–704. [PubMed]
  • MacCollin M, Ramesh V, Jacoby LB, Louis DN, Rubio MP, Pulaski K, Trofatter JA, Short MP, Bove C, Eldridge R, et al. Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet. 1994 Aug;55(2):314–320. [PMC free article] [PubMed]
  • Bourn D, Carter SA, Mason S, Gareth D, Evans R, Strachan T. Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. Hum Mol Genet. 1994 May;3(5):813–816. [PubMed]
  • Mérel P, Hoang-Xuan K, Sanson M, Bijlsma E, Rouleau G, Laurent-Puig P, Pulst S, Baser M, Lenoir G, Sterkers JM, et al. Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer. 1995 Feb;12(2):117–127. [PubMed]
  • Evans DG, Bourn D, Wallace A, Ramsden RT, Mitchell JD, Strachan T. Diagnostic issues in a family with late onset type 2 neurofibromatosis. J Med Genet. 1995 Jun;32(6):470–474. [PMC free article] [PubMed]
  • Kluwe L, Bayer S, Baser ME, Hazim W, Haase W, Fünsterer C, Mautner VF. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet. 1996 Nov;98(5):534–538. [PubMed]
  • Parry DM, MacCollin MM, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Bolesta M, Eldridge R, Gusella JF. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996 Sep;59(3):529–539. [PMC free article] [PubMed]
  • Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet. 1996 Aug;59(2):331–342. [PMC free article] [PubMed]
  • Evans DG, Trueman L, Wallace A, Collins S, Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet. 1998 Jun;35(6):450–455. [PMC free article] [PubMed]
  • Kluwe L, MacCollin M, Tatagiba M, Thomas S, Hazim W, Haase W, Mautner VF. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet. 1998 May 18;77(3):228–233. [PubMed]
  • Bourn D, Carter SA, Evans DG, Goodship J, Coakham H, Strachan T. A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals. Am J Hum Genet. 1994 Jul;55(1):69–73. [PMC free article] [PubMed]
  • Bijlsma EK, Wallace AJ, Evans DG. Misleading linkage results in an NF2 presymptomatic test owing to mosaicism. J Med Genet. 1997 Nov;34(11):934–936. [PMC free article] [PubMed]
  • Kluwe L, Mautner VF. Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet. 1998 Dec;7(13):2051–2055. [PubMed]
  • Zucman-Rossi J, Legoix P, Der Sarkissian H, Cheret G, Sor F, Bernardi A, Cazes L, Giraud S, Ollagnon E, Lenoir G, et al. NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet. 1998 Dec;7(13):2095–2101. [PubMed]
  • Sainz J, Figueroa K, Baser ME, Mautner VF, Pulst SM. High frequency of nonsense mutations in the NF2 gene caused by C to T transitions in five CGA codons. Hum Mol Genet. 1995 Jan;4(1):137–139. [PubMed]
  • Kondziolka D, Lunsford LD, McLaughlin MR, Flickinger JC. Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med. 1998 Nov 12;339(20):1426–1433. [PubMed]
  • Ruttledge MH, Narod SA, Dumanski JP, Parry DM, Eldridge R, Wertelecki W, Parboosingh J, Faucher MC, Lenoir GM, Collins VP, et al. Presymptomatic diagnosis for neurofibromatosis 2 with chromosome 22 markers. Neurology. 1993 Sep;43(9):1753–1760. [PubMed]
  • Baser ME, Mautner VF, Ragge NK, Nechiporuk A, Riccardi VM, Klein J, Sainz J, Pulst SM. Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations. Neurology. 1996 Nov;47(5):1269–1277. [PubMed]
  • Evans DG, Maher ER, Macleod R, Davies DR, Craufurd D. Uptake of genetic testing for cancer predisposition. J Med Genet. 1997 Sep;34(9):746–748. [PMC free article] [PubMed]
  • Evans DG, Mason S, Huson SM, Ponder M, Harding AE, Strachan T. Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. J Neurol Neurosurg Psychiatry. 1997 Apr;62(4):361–366. [PMC free article] [PubMed]
  • Jacoby LB, Jones D, Davis K, Kronn D, Short MP, Gusella J, MacCollin M. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet. 1997 Dec;61(6):1293–1302. [PMC free article] [PubMed]
  • Honda M, Arai E, Sawada S, Ohta A, Niimura M. Neurofibromatosis 2 and neurilemmomatosis gene are identical. J Invest Dermatol. 1995 Jan;104(1):74–77. [PubMed]
  • Allen J, Eldridge R, Koerber T. Acoustic neuroma in the last months of pregnancy. Am J Obstet Gynecol. 1974 Jun 15;119(4):516–520. [PubMed]
  • Evans DG, Blair V, Strachan T, Lye RH, Ramsden RT. Variation of expression of the gene for type 2 neurofibromatosis: absence of a gender effect on vestibular schwannomas, but confirmation of a preponderance of meningiomas in females. J Laryngol Otol. 1995 Sep;109(9):830–835. [PubMed]
  • Baser ME, Ragge NK, Riccardi VM, Janus T, Gantz B, Pulst SM. Phenotypic variability in monozygotic twins with neurofibromatosis 2. Am J Med Genet. 1996 Sep 6;64(4):563–567. [PubMed]
  • Sainio M, Zhao F, Heiska L, Turunen O, den Bakker M, Zwarthoff E, Lutchman M, Rouleau GA, Jäskeläinen J, Vaheri A, et al. Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci. 1997 Sep;110(Pt 18):2249–2260. [PubMed]
  • Xu HM, Gutmann DH. Merlin differentially associates with the microtubule and actin cytoskeleton. J Neurosci Res. 1998 Feb 1;51(3):403–415. [PubMed]
  • Gutmann DH, Geist RT, Xu H m, Kim JS, Saporito-Irwin S. Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet. 1998 Mar;7(3):335–345. [PubMed]
  • Gutmann DH, Sherman L, Seftor L, Haipek C, Hoang Lu K, Hendrix M. Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading. Hum Mol Genet. 1999 Feb;8(2):267–275. [PubMed]
  • Grönholm M, Sainio M, Zhao F, Heiska L, Vaheri A, Carpén O. Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. J Cell Sci. 1999 Mar;112(Pt 6):895–904. [PubMed]
  • Tsukita S, Yonemura S. Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins. J Biol Chem. 1999 Dec 3;274(49):34507–34510. [PubMed]
  • Hiscox S, Jiang WG. Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin. J Cell Sci. 1999 Sep;112(Pt 18):3081–3090. [PubMed]
  • Maeda M, Matsui T, Imamura M, Tsukita S, Tsukita S. Expression level, subcellular distribution and rho-GDI binding affinity of merlin in comparison with Ezrin/Radixin/Moesin proteins. Oncogene. 1999 Aug 26;18(34):4788–4797. [PubMed]
  • Bretscher A. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol. 1999 Feb;11(1):109–116. [PubMed]
  • Sherman L, Xu HM, Geist RT, Saporito-Irwin S, Howells N, Ponta H, Herrlich P, Gutmann DH. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene. 1997 Nov 13;15(20):2505–2509. [PubMed]
  • Gutmann DH, Giordano MJ, Fishback AS, Guha A. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology. 1997 Jul;49(1):267–270. [PubMed]
  • Huynh DP, Mautner V, Baser ME, Stavrou D, Pulst SM. Immunohistochemical detection of schwannomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas. J Neuropathol Exp Neurol. 1997 Apr;56(4):382–390. [PubMed]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...